AbbVie said 23 abstracts, including data on approved and investigational oncology medicines, have been accepted for presentations at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO) on June 2-6 in Chicago.
"AbbVie's data presentations at this year's ASCO meeting reinforce our diverse and comprehensive oncology pipeline, focused on bringing new medicines to patients, especially in areas where few options exist in cancer," AbbVie Vice President of Oncology Discovery and Early Development Tom Hudson said in an AbbVie release. "By combining our deep knowledge in core areas of biology with cutting-edge technologies, and working together with our partners including scientists, industry peers and patients, we aim to discover and develop medicines that will drive transformational improvements in cancer treatment."
The abstracts to be presented will cover tumors that include brain cancer, breast cancer, lung cancer and hematologic malignancies, the release said.
The latest data on depatuxizumab mafodotin (ABT-414) in treating amplified-epidermal growth factor receptor (EGFR) glioblastoma (GBM) in adults will be presented. GBM is a highly aggressive brain cancer that develops in the brain's supportive tissues. Patients with GMB have a five-year survival rate of approximately 6 percent. Approximately 50 percent of GBM malignancies include EGFR amplification.
AbbVie researchers will also present four abstracts on ibrutinib, three on venetoclax, five on rovalpituzumab tesirine (Rova-T), four on veliparib, two on elotuzumab, one on ABBV-221, two on ABBV-399 and one on ABT-348.